Yelena Mikhailov

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

H. Colman, B. V. Van Tine, S. Guichard, 2022, Neuro-oncology.

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.

H. Colman, M. Milhem, M. Rosenthal, 2020 .

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.

Robin L. Jones, J. Blay, A. Italiano, 2020 .